聚乙二醇干扰素治疗慢性乙型肝炎诱发血栓性血小板减少性紫癜1例报告

王欣茹; 肖丽; 耿爱文; 咸建春

doi:10.3969/j.issn.1001-5256.2020.11.028

聚乙二醇干扰素治疗慢性乙型肝炎诱发血栓性血小板减少性紫癜1例报告

DOI: 10.3969/j.issn.1001-5256.2020.11.028

泰州市人民医院肝病科

基金项目:

泰州市科技支撑计划（社会发展）项目（TS201813）；

详细信息

中图分类号: R512.62;R554.6;R558.2
计量
- 文章访问数: 713
- HTML全文浏览量: 19
- PDF下载量: 68
- 被引次数: 0
出版历程
- 出版日期: 2020-11-20

Pegylated interferon for treatment of chronic hepatitis B-induced thrombotic thrombocytopenic purpura:A case report

Department of Hepatology,Taizhou People's Hospital

Research funding:

摘要

摘要:
<正>目前用于治疗慢性乙型肝炎（CHB）的药物主要为干扰素（IFN）及核苷（酸）类药物（NAs）两类[1]。IFN治疗的优势包括疗程有限、应答更持久以及不产生耐药,也是目前有望提高功能性治愈率、达到理想治疗终点的主要药物[2]。但IFN不良反应较多,极少数可出现严重不良反应,如免疫性血小板减少性紫癜及血栓性血小板减少性紫癜（thrombotic thrombocytopenic purpura,TTP）[3]。通过报道1例可能与PEG-IFNα-2a治疗CHB相关的致死性TTP,以提醒临床医生加以注意。
- 乙型肝炎,慢性 /
- 紫癜,血栓性血小板减少性 /
- 干扰素α
- hepatitis B,chronic /
- purpura,thrombotic thrombocytopenic /
- interferon-alpha

HTML全文

参考文献(15)

[1] Chinese Society of Hepatology and Chinese Society of Infectious Diseases,Chinese Medical Association. The guideline of prevention and treatment for chronic hepatitis B:A 2015 update[J]. J Clin Hepatol,2015,31(12):1941-1960.(in Chinese)中华医学会肝病学分会，中华医学会感染病学分会．慢性乙型肝炎防治指南(2015年更新版)[J]．临床肝胆病杂志，2015,31(12):1941-1960.

[2] Chinese society of infectious diseases,Chinese society of hepatology. The expert consensus on functional cure of chronic hepatitis B[J]. J Chin Hepatol,2019,35(8):1693-1701.(in Chinese)中华医学会感染病学分会，中华医学会肝病学分会．慢性乙型肝炎临床治愈(功能性治愈)专家共识[J]．临床肝胆病杂志，2019,35(8):1693-1701.

[3] LI L,LYU J,XIAO M,et al. Clinical characteristics of severe thrombocytopenic purpura induced by interferon in 27 cases[J].World Chin J Dig,2009,17(11):1147-1151.(in Chinese)李丽，闾军，肖默，等．干扰素诱导的严重血小板减少性紫癜临床特点分析27例[J]．世界华人消化杂志，2009,17(11):1147-1151.

[4] Thrombosis and hemostasis group,hematology branch,Chinese medical association. Chinese expert consensus on diagnosis and treatment of thrombotic thrombocytopenic purpura(2012 edition)[J]. J Chin Hematol,2012,33(11):983-984.(in Chinese)中华医学会血液学分会血栓与止血学组．血栓性血小板减少性紫癜诊断与治疗中国专家共识(2012年版)[J]．中华血液学杂志，2012,33(11):983-984.

[5] LI B,GAO R,LI R,et al. Study on the methods to determine the association of adverse reactions/adverse events in drug clinical trials[J]. Chin J New Drugs,2014,23(12):1465-1470.(in Chinese)李博，高蕊，李睿，等．药物临床试验不良反应/不良事件关联性判定方法研究探讨[J]．中国新药杂志，2014,23(12):1465-1470.

[6] TERRAULT NA,LOK A,MCMAHON BJ,et al. Update on prevention, diagnosis, and treatment of chronic hepatitis B:AASLD 2018 hepatitis B guidance[J]. Hepatology,2018,67(4):1560-1599.

[7] ZHANG Y,ZHANG L,CHEN M,et al. Clinical analysis of 10cases of refractory/recurrent thrombocytopenic purpura treated with rituximab combined regimen[J]. J Chin Hematol,2018,39(10):855-858.(in Chinese)张炎，张路，陈苗，等．含利妥昔单抗联合方案治疗难治/复发血栓性血小板减少性紫癜10例临床分析[J]．中华血液学杂志，2018,39(10):855-858.

[8] WAZNY LD,ARIANO RE. Evaluation and management of druginduced thrombocytopenia in the acutely ill patient[J]. Pharmacotherapy,2000,20(3):292-307.

[9] IYODA K,KATO M,NAKAGAWA T,et al. Thrombotic thrombocytopenic purpura developed suddenly during interferon treatment for chronic hepatitis C[J]. J Gastroenterol,1998,33(4):588-592.

[10] KUNDRA A,WANG JC. Interferon induced thrombotic microangiopathy(TMA):Analysis and concise review[J]. Crit Rev Oncol Hematol,2017,112:103-112.

[11] DEUTSCH M,MANESIS EK,HADZIYANNIS E,et al. Thrombotic thrombocytopenic purpura with fatal outcome in a patient with chronic hepatitis C treated with pegylated interferon-a/2b[J]. Scand J Gastroenterol,2007,42(3):408-409.

[12] PODDAR N,WANG JC. Thrombotic thrombocytopenic purpura in a patient with interferon treated hepatitis C successfully treated with rituximab[J]. Hematol Rep,2013,5(1):5-7.

[13] DING L,QIAN Z,ZHANG YH,et al. One case of thrombotic thrombocytopenic purpura during treatment with hepatitis B interferon[J]. J Chin Hematol,2016,37(12):1037.(in Chinese)丁磊，钱琤，张宇浩，等．乙型肝炎干扰素治疗期间合并血栓性血小板减少性紫癜一例[J]．中华血液学杂志，2016,37(12):1037.

[14] Expert committee on clinical management of therapeutic side effects of interferon in patients with chronic viral hepatitis.Chronic viral hepatitis patients with interferon treatment of adverse reactions clinical treatment experts consensus[J/CD].Chin J Exp Clin Infect Dis(Electronic Edition),2014,8(1):96-101.(in Chinese)慢性病毒性肝炎患者干扰素α治疗不良反应临床处理专家委员会．慢性病毒性肝炎患者干扰素α治疗不良反应临床处理专家共识[J/CD]．中华实验和临床感染病杂志(电子版)，2014,8(1):96-101.

[15] ZHANG WH,ZHANG DZ,DOU XG,et al. Expert consensus on the treatment of chronic hepatitis B with peg interferon beta[J]. Chin J Hepatol,2017,25(9):678-686.(in Chinese)张文宏，张大志，窦晓光，等．聚乙二醇干扰素α治疗慢性乙型肝炎专家共识[J]．中华肝脏病杂志，2017,25(9):678-686.

施引文献

资源附件(0)

访问统计